Icon

ICON launches FIRECREST Pre-Screen

Tuesday, November 28, 2017

ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, announced the launch of FIRECREST Pre-Screen, an innovative digital solution that increases the efficiency and quality of initial patient eligibility assessments. FIRECREST Pre-Screen provides a more robust solution for site personnel to identify potentially eligible patients which can lead to improved enrolment rates and reduced costs by preventing ineligible patients from progressing to the full screening stage.

[Read More]

Voice assistant technology poised to fundamentally transform clinical research

Monday, November 13, 2017

Within the next five to 10 years, patients enrolled in research studies will using voice assistant technology such as Amazon Alexa or Google Assistant to interact with clinical trials. Experts expect that these voice assist devices will bolster patient engagement, and may eventually streamline the research enterprise for sponsors and site coordinators as well. On Wednesday, November 8, ICON demonstrated Amazon Alexa’s capacity to deploy a commonly used research questionnaire at the ISPOR 20th Annual European Congress in Glasgow, Scotland. According to Muehlhausen, controlled studies are “the next step” for ICON. “We have a pharma company that has already committed to run a scientific exercise in which we’ll compare Alexa versus an IVR system or a paper system.”

[Read More]

Insys Therapeutics founder arrested on charges of racketeering

Monday, November 6, 2017

On the very same day President Donald Trump declared the opioid crisis to be a nationwide public health emergency, Insys Therapeutics founder and majority owner John Kapoor was arrested. He was charged with leading a nationwide conspiracy to profit by using bribes and fraud to cause the illegal distribution of his company’s Fentanyl spray, Subsys, intended for cancer patients experiencing breakthrough pain. 

[Read More]

Integrated delivery of CRO services

Friday, September 1, 2017

Unified delivery of a broad range of services by a CRO within a single clinical trial can be difficult to do as each role within a CRO—be it a Clinical, Data or Laboratory Project Manager, is primarily focused on delivery of their own aspects of the trial.

[Read More]

Three Questions: Bill Row, Icon

Friday, September 1, 2017

CWWeekly presents this biweekly feature as a spotlight on issues that executives in clinical research face. This week, writer Sony Salzman spoke with Bill Row, MBA, MS, divisional principal, Real World Evidence, Commercialization & Outcomes, at Icon. His focus is commercial applications of real-world evidence late phase studies for both pharmaceutical companies and CROs.

[Read More]

New EU medical device regulations cause industry shake up

Monday, August 21, 2017

Medical device manufacturers will need to provide substantially more clinical evidence to support claims of safety and performance for many medical and in vitro diagnostic (IVD) devices marketed in the European Union (EU) as the result of two new regulations adopted by the European Parliament.

[Read More]